Skip to content

Use of Multiple Medicines in Patients With High Blood Pressure

To Study The Prevalence Of Polypharmacy Among Patients With Hypertension At Tertiary Care Centre - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/02/103384
Enrollment
241
Registered
2026-02-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Nil: Nil

Sponsors

Aniruddha Sinha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults of either gender. Age should be more than 30 years and above. Individuals having systolic blood pressure of 140-179mmHg and diastolic blood pressure of 90-109mmHg. Hypertensive patients. Hypertensive patients with co morbid conditions such as diabetes mellitus etc.

Exclusion criteria

Exclusion criteria: Patients who did not give informed consent. Patients less than 18 years and more than 80 years old. Patients with severe illness such as chronic kidney disease, malignancy. etc. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Prevalence of polypharmacy among hypertensive patients, defined as the proportion of patients receiving five or more concurrent prescribed medications at a tertiary care center.Timepoint: At the time of outpatient department baseline than every 1 week till study

Secondary

MeasureTime frame
Appropriateness of polypharmacy among hypertensive patients, categorized as appropriate or inappropriate based on standard clinical guidelinesTimepoint: At the time of outpatient department baseline than every 1 week till study

Countries

India

Contacts

Public ContactDr Aniruddha Sinha

Baba Raghav Das Medical College Gorakhpur

rishu0722@gmail.com9155977216

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026